A Combination Therapy of pHRE-Egr1-HSV-TK/Anti-CD133McAb-131I/MFH Mediated by FePt Nanoparticles for Liver Cancer Stem Cells

It has been evidenced that liver cancer stem cells (LCSCs) are to blame hepatocellular carcinoma (HCC) occurrence, development, metastasis, and recurrence. Using iron-platinum nanoparticles (FePt-NPs) as a carrier and CD133 antigen as a target, a new strategy to targetly kill LCSCs by integrating HS...

Full description

Bibliographic Details
Main Authors: Mei Lin, Yanhong Xiao, Xingmao Jiang, Jun Zhang, Ting Guo, Yujuan Shi
Format: Article
Language:English
Published: Hindawi Limited 2020-01-01
Series:Journal of Nanomaterials
Online Access:http://dx.doi.org/10.1155/2020/7180613
id doaj-3c4c57388d964a2aa059973538731837
record_format Article
spelling doaj-3c4c57388d964a2aa0599735387318372020-11-25T03:10:47ZengHindawi LimitedJournal of Nanomaterials1687-41101687-41292020-01-01202010.1155/2020/71806137180613A Combination Therapy of pHRE-Egr1-HSV-TK/Anti-CD133McAb-131I/MFH Mediated by FePt Nanoparticles for Liver Cancer Stem CellsMei Lin0Yanhong Xiao1Xingmao Jiang2Jun Zhang3Ting Guo4Yujuan Shi5Clinical Laboratory, Taizhou People’s Hospital Affiliated to Nantong University, Taizhou, Jiangsu 225300, ChinaImaging Department, Taizhou People’s Hospital Affiliated to Nantong University, Taizhou, Jiangsu 225300, ChinaHubei Key Lab of Novel Reactor & Green Chemical Technology, Key Laboratory for Green Chemical Process of Ministry of Education, School of Chemical Engineering and Pharmacy, Wuhan Institute of Technology, Wuhan 430205, ChinaIsotopic Laboratory, Taizhou People’s Hospital Affiliated to Nantong University, Taizhou, Jiangsu 225300, ChinaInstitute of Clinical Medicine, Taizhou People’s Hospital Affiliated to Nantong University, Taizhou, Jiangsu 225300, ChinaImaging Department, Taizhou People’s Hospital Affiliated to Nantong University, Taizhou, Jiangsu 225300, ChinaIt has been evidenced that liver cancer stem cells (LCSCs) are to blame hepatocellular carcinoma (HCC) occurrence, development, metastasis, and recurrence. Using iron-platinum nanoparticles (FePt-NPs) as a carrier and CD133 antigen as a target, a new strategy to targetly kill LCSCs by integrating HSV-TK suicide gene, 131I nuclide irradiation, and magnetic fluid hyperthermia (MFH) together was designed and investigated in the present study. The results showed that FePt-NPs modified with PEI (PEI-FePt-NPs) could bind with DNA, and the best binding ratio was 1 : 40 (mass ratio). Moreover, DNA binding to PEI-FePt-NPs could refrain from Dnase1 enzyme digestion and could release under certain conditions. LCSCs (CD133+ Huh-7 cells) were transfected with pHRE-Egr1-HSV-TK by PEI-FePt-NPs, and the transfection efficiency was 53.65±3.40%. These data showed a good potential of PEI-FePt-NPs as a gene transfer carrier.131I was labeled with anti-CD133McAb in order to facilitate therapy targeting. The combined intervention of pHRE-Egr1-HSV-TK/anti-CD133McAb-131I/MFH mediated by PEI-FePt-NPs could greatly inhibit LCSCs’ growth and induce cell apoptosis in vitro, significantly higher than any of the individual interventions (p<0.05). This study offers a practicable idea for LCSC treatment, and PEI-FePt-NPs may act as novel nonviral gene vectors and a magnetic induction medium.http://dx.doi.org/10.1155/2020/7180613
collection DOAJ
language English
format Article
sources DOAJ
author Mei Lin
Yanhong Xiao
Xingmao Jiang
Jun Zhang
Ting Guo
Yujuan Shi
spellingShingle Mei Lin
Yanhong Xiao
Xingmao Jiang
Jun Zhang
Ting Guo
Yujuan Shi
A Combination Therapy of pHRE-Egr1-HSV-TK/Anti-CD133McAb-131I/MFH Mediated by FePt Nanoparticles for Liver Cancer Stem Cells
Journal of Nanomaterials
author_facet Mei Lin
Yanhong Xiao
Xingmao Jiang
Jun Zhang
Ting Guo
Yujuan Shi
author_sort Mei Lin
title A Combination Therapy of pHRE-Egr1-HSV-TK/Anti-CD133McAb-131I/MFH Mediated by FePt Nanoparticles for Liver Cancer Stem Cells
title_short A Combination Therapy of pHRE-Egr1-HSV-TK/Anti-CD133McAb-131I/MFH Mediated by FePt Nanoparticles for Liver Cancer Stem Cells
title_full A Combination Therapy of pHRE-Egr1-HSV-TK/Anti-CD133McAb-131I/MFH Mediated by FePt Nanoparticles for Liver Cancer Stem Cells
title_fullStr A Combination Therapy of pHRE-Egr1-HSV-TK/Anti-CD133McAb-131I/MFH Mediated by FePt Nanoparticles for Liver Cancer Stem Cells
title_full_unstemmed A Combination Therapy of pHRE-Egr1-HSV-TK/Anti-CD133McAb-131I/MFH Mediated by FePt Nanoparticles for Liver Cancer Stem Cells
title_sort combination therapy of phre-egr1-hsv-tk/anti-cd133mcab-131i/mfh mediated by fept nanoparticles for liver cancer stem cells
publisher Hindawi Limited
series Journal of Nanomaterials
issn 1687-4110
1687-4129
publishDate 2020-01-01
description It has been evidenced that liver cancer stem cells (LCSCs) are to blame hepatocellular carcinoma (HCC) occurrence, development, metastasis, and recurrence. Using iron-platinum nanoparticles (FePt-NPs) as a carrier and CD133 antigen as a target, a new strategy to targetly kill LCSCs by integrating HSV-TK suicide gene, 131I nuclide irradiation, and magnetic fluid hyperthermia (MFH) together was designed and investigated in the present study. The results showed that FePt-NPs modified with PEI (PEI-FePt-NPs) could bind with DNA, and the best binding ratio was 1 : 40 (mass ratio). Moreover, DNA binding to PEI-FePt-NPs could refrain from Dnase1 enzyme digestion and could release under certain conditions. LCSCs (CD133+ Huh-7 cells) were transfected with pHRE-Egr1-HSV-TK by PEI-FePt-NPs, and the transfection efficiency was 53.65±3.40%. These data showed a good potential of PEI-FePt-NPs as a gene transfer carrier.131I was labeled with anti-CD133McAb in order to facilitate therapy targeting. The combined intervention of pHRE-Egr1-HSV-TK/anti-CD133McAb-131I/MFH mediated by PEI-FePt-NPs could greatly inhibit LCSCs’ growth and induce cell apoptosis in vitro, significantly higher than any of the individual interventions (p<0.05). This study offers a practicable idea for LCSC treatment, and PEI-FePt-NPs may act as novel nonviral gene vectors and a magnetic induction medium.
url http://dx.doi.org/10.1155/2020/7180613
work_keys_str_mv AT meilin acombinationtherapyofphreegr1hsvtkanticd133mcab131imfhmediatedbyfeptnanoparticlesforlivercancerstemcells
AT yanhongxiao acombinationtherapyofphreegr1hsvtkanticd133mcab131imfhmediatedbyfeptnanoparticlesforlivercancerstemcells
AT xingmaojiang acombinationtherapyofphreegr1hsvtkanticd133mcab131imfhmediatedbyfeptnanoparticlesforlivercancerstemcells
AT junzhang acombinationtherapyofphreegr1hsvtkanticd133mcab131imfhmediatedbyfeptnanoparticlesforlivercancerstemcells
AT tingguo acombinationtherapyofphreegr1hsvtkanticd133mcab131imfhmediatedbyfeptnanoparticlesforlivercancerstemcells
AT yujuanshi acombinationtherapyofphreegr1hsvtkanticd133mcab131imfhmediatedbyfeptnanoparticlesforlivercancerstemcells
AT meilin combinationtherapyofphreegr1hsvtkanticd133mcab131imfhmediatedbyfeptnanoparticlesforlivercancerstemcells
AT yanhongxiao combinationtherapyofphreegr1hsvtkanticd133mcab131imfhmediatedbyfeptnanoparticlesforlivercancerstemcells
AT xingmaojiang combinationtherapyofphreegr1hsvtkanticd133mcab131imfhmediatedbyfeptnanoparticlesforlivercancerstemcells
AT junzhang combinationtherapyofphreegr1hsvtkanticd133mcab131imfhmediatedbyfeptnanoparticlesforlivercancerstemcells
AT tingguo combinationtherapyofphreegr1hsvtkanticd133mcab131imfhmediatedbyfeptnanoparticlesforlivercancerstemcells
AT yujuanshi combinationtherapyofphreegr1hsvtkanticd133mcab131imfhmediatedbyfeptnanoparticlesforlivercancerstemcells
_version_ 1715285494159376384